While preclinical data demonstrate the efficacy of targeting OATP1A2 in models of GI tumors, data remain limited regarding the specific function of OATP1A2 in regulating nondepolarizing neuromuscular blocking drugs. The gene discussed is SLCO1A2; the disease is digestive system neoplasm.